Natural product-based anti-ageing and Lifespan extension therapy: A pharmaceutical mixture encompassing Curcumin and Dasatinib (CAD)  increases CHIP levels, increases monoubiquitylation of insulin receptor (INSR), decreases INSR protein levels and enhances lifespan, via down regulation of its target gene, 24/August/2019, 12.05 am

Combinatorial therapy for autoimmune diabetes  (TIDM):   A pharmaceutical mixture encompassing Dulaglutide (trade name: Trulicity), a Glucagon-like peptide-1  (GLP-1) receptor agonist, and Verapamil (brand name: Calanm, Isoptin and others), an anti-hypertensive drug,  increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 23/August/2019, 11.38 pm
August 23, 2019
The Mechanistic basis of how Liraglutide mitigates complications of diabetes and obesity:  Liraglutide (trade name: Victoza, Saxenda), a Glucagon-like peptide-1  (GLP-1) receptor agonist,  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates diabetes mellitus, via down regulation of its target gene, 24/August/2019, 12.27 am
August 23, 2019
Show all

Introduction: What they say 

A study from Institute for Cell Biology, University of Bonn, Ulrich-Haberland Str.  Bonn, Germany; and Institute for Genetics and CECAD Research Center, University of Cologne, Joseph-Stelzmann Str. Cologne, Germany shows that “The Ubiquitin Ligase CHIP Integrates Proteostasis and Aging by Regulation of Insulin Receptor Turnover.” This research paper was published, in the 20 April 2017 issue of the journal “Cell” [One of the best research journals in Biology with an I.F of 28 plus], by Prof. Hoppe TTawo R and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based anti-ageing and Lifespan extension therapy: A pharmaceutical mixture encompassing Curcumin and Dasatinib (CAD)  increases CHIP levels, increases monoubiquitylation of insulin receptor (INSR), decreases INSR protein levels and enhances lifespan, via down regulation of its target gene


What is known?

Prof. Hoppe T’s research team has recently shown that knocking down CHIP gene in mice results in a) increased protein levels of insulin receptor (INSR); and b) reduced lifespan. Further, they have shown that CHIP targets INSR for mono ubiquitylation and degradation, while its ability to degrade INSR is compromised upon proteotoxic stress and during ageing, as CHIP is directed toward disposal of misfolded proteins, rather than degrade the INSR.


From Research findings to Therapeutic opportunity:

This study suggests a vitmain-based anti-ageing therapy. A pharmaceutical mixture encompassing Curcumin and Dasatinib (CAD), by increasing the expression of its target gene, it may increase the levels of CHIP (carboxy terminus of Hsc70 interacting protein). Thereby, it may: (1) increase CHIP-assisted proteolysis; (2) increase mono ubiquitylation and degradation of INSR (Insulin receptor); (3) inhibit the insulin and IGF1 signaling pathway; and (4) enhance longevity (Fig1).

Figure 1. Mechanistic insights into how a pharmaceutical mixture encompassing Curcumin and Dasatinib (CAD) induces CHIP expression and extends lifespan

Figure 2. The chemical structure of  Curcumin and Dasatinib (CAD). CAD enhances folding of proteins, prevents protein aggregation and extends life span through induction of CHIP. 

Figure 3. While it has been shown that genetic deletion of CHIP1 reduces longevity in worms and others, this study suggests, for the first time, that a pharmaceutical mixture encompassing Curcumin and Dasatinib (CAD) could extend lifespan through induction of CHIP1

Thus, pharmacological formulations encompassing “a pharmaceutical mixture encompassing Curcumin and Dasatinib (CAD) or their analogues, either alone or in combination with compounds,may be used to suppress age-associated overall physiological decline and improve health/life span.


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How a pharmaceutical mixture encompassing Curcumin and Dasatinib (CAD) decreases the levels of INSR and promotes longevity

Amount:$ 1, 500#

# Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Natural product-based anti-ageing and Lifespan extension therapy: A pharmaceutical mixture encompassing Curcumin and Dasatinib (CAD)  increases CHIP levels, increases monoubiquitylation of insulin receptor (INSR), decreases INSR protein levels and enhances lifespan, via down regulation of its target gene, 24/August/2019, 12.05 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, kindly drop us a line at info@genomediscovery.org

Comments are closed.